Chief Medical Officer Cornelis Wortel, MD, PhD at Ichor in LaFayette, NY

Industry Leader Joins Ichor Therapeutics as Chief Medical Officer

Posted Posted in Antoxerene, Ichor, Lysoclear

Ichor Therapeutics, a pre-clinical contract research organization, recently announced the appointment of Cornelis (Cees) Hendrik Wortel MD, PhD to the position of Chief Medical Officer (CMO). Dr. Wortel brings over 25 years of experience to Ichor, having worked as a senior (bio) pharmaceutical executive for early stage and established companies, both nationally and internationally. Most notably, he has been involved in the development of Remicade® (the first anti-TNF biological drug) and in a very large number of clinical trials, Phase I to IV, bringing innovative first-in-class drugs to market.

Scientist at Ichor in LaFayette, NY

Ichor Unveils Orally Bioavailable Antibody-like Scaffold in ACS Biochemistry

Posted Posted in Antoxerene, Ichor, RecombiPure

A landmark biotechnology was published for the first time in the peer-reviewed journal ACS Biochemistry. The article, “RPtag as an orally bioavailable, hyper stable epitope tag and generalizable protein binding scaffold,” describes a foundational technology that could have huge implications in drug discovery, diagnostics, and clinical antibody therapy.

Ichor CEO Delivers Keynote at TriBeta Northeast Conference

Posted Posted in Ichor

The State University of New York at Fredonia hosted the Northeastern District-3 Conference for TriBeta, the Biology Honor Society. Kelsey Moody, CEO at Ichor Therapeutics, delivered the keynote address. In the address, he discussed Ichor’s humble beginnings in a West Syracuse apartment, and encouraging pre-clinical results from the company’s age-related macular degeneration program.

Ichor to Present Double Feature at Undoing Aging Conference in Berlin

Posted Posted in Antoxerene, Ichor, Lysoclear

The 2018 Undoing Aging Conference, co-hosted by SENS Research Foundation and Michael Greve’s Forever Healthy Foundation, is a scientific forum focused on the cellular and molecular repair of age-related damage. It provides a platform for leading researchers from around the world to share their work in stem cells, senescent cells, immunotherapies, biomarkers, and drug discovery.